Inve US ▾

Dexcom (DXCM) earnings

DEXCOM INC· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Dexcom earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,308 $ million+13.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin24.3 %+6.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit249 $ million+38.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

9 of 9 judged targets kept · 7 open · verdicts reflect calls analysed to Jun 2026.

DEXCOM INC management guidance track record: 16 targets tracked across analysed earnings calls (9 achieved, 0 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Commercial PBM coverage for type 2 non-insulin diabetes livesMore than 7 million type 2 non-insulin lives covered by the end of 2026Mar 2026Jun 2026:we now have coverage for all people with diabetes across the 4 largest commercial PBMs. This represents reimbursement for more than 7 million people with type 2 diabetes who are not on insulin.
Call transcript, Jun 2026 · no direct link		Achieved
Full-year adjusted EBITDA margin guidanceapproximately 30% to 31%Dec 2025Jun 2026:adjusted EBITDA margin guidance to a range of 31.5% to 32%
Call transcript, Jun 2026 · no direct link		Revised Up

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of DEXCOM INC's 16 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$85.98 −0.07% · −$0.06

Last close Oct 19, 2026 · US · USD

Performance +29.1% 1Y

$60.0$70.0$80.0$90.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Aug 26Oct 26Mar 2026 (Q1 FY26) — 30 Apr 2026Jun 2026 (Q2 FY26) — 30 Jul 2026

1Y: $66.6 on 17 Oct 2025 → $85.98. High $92.34 (21 Aug 2026), low $54.84 (10 Nov 2025).

Previous close
$86.04
52-week range
$54.84 – $92.34
One year
+25.65%

Overview

Symbol
DXCM
Exchange
US
Currency
USD

Your own record

Start an Inve Case for DEXCOM INC

Free account. Everything above stays public.

Write why you follow DEXCOM INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under D

All 114 companies under D

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered